Lytix to Take Lead Antimicrobial Compound into Clinic; Novel antimicrobial shows increased efficacy versus gold standard
TROMS0, Norway--The Scandinavian-based drug development company Lytix Biopharma announced its intention to take its lead ultra-broad spectrum antimicrobial through to clinical trials. Broadly effective through rapid and selective cell lysis against even highly resistant bacterial strains such as MRSA, this novel class of small molecules exhibits an extremely low propensity for resistance development.
According to Lytix Biopharma CEO Oystein Rekdal, extensive preclinical studies have documented excellent efficacy for topical treatment: "Animal skin infection studies at the State Serum Institute in Copenhagen showed outstanding efficacy against Gram positive bacteria. Indeed, complete eradication of the test organism was obtained within 24 hours, considered vastly superior to Gold Standard treatments. Additional data shows that our lead compound has an unusually broad efficacy spectrum, including the Gram negative Pseudomonas species as well as yeasts and fungi. Toxicology and formulation work is already underway and we expect to able to submit our IND in the beginning of 2009. We have now chosen to partner with SAFC Pharma for the production of our lead compound in support of clinical trials."
About Lytix Biopharma AS
The Scandinavian based company Lytix Biopharma commercialise world-class research in synthetic peptide therapeutics by its founding scientists working in the University Hospital and University of Troms in Norway. The initial pipeline includes micro-size synthetic antimicrobial peptides (SAMPs(TM)) for the treatment of multiresistant bacteria, fungal infections and cancer.
In addition to equity, the company and its research programme has received substantial grants from the Norwegian Research Council through its BIA and FUGE programmes. Lytix operates from state-of-the-art laboratories in the Troms Science Park with business development in Oslo. The development team has extensive experience of developing peptide based drugs, including preparation of peptides and peptidomimetics, synthesis of non-coded amino acids, medicinal chemistry, pharmacokinetics, QSAR and peptide drug design.
www.lytixbiopharma.com
Contacts
Corporate Inquiries
Lytix Biopharma AS
Oystein Rekdal - CEO
Tel +47 97 57 33 58
oystein.rekdal@lytixbiopharma.com
or
Media Inquiries
Hayhurst Media
Richard Hayhurst, +44 (0) 7711821527
Richard@hayhurstmedia.com
According to Lytix Biopharma CEO Oystein Rekdal, extensive preclinical studies have documented excellent efficacy for topical treatment: "Animal skin infection studies at the State Serum Institute in Copenhagen showed outstanding efficacy against Gram positive bacteria. Indeed, complete eradication of the test organism was obtained within 24 hours, considered vastly superior to Gold Standard treatments. Additional data shows that our lead compound has an unusually broad efficacy spectrum, including the Gram negative Pseudomonas species as well as yeasts and fungi. Toxicology and formulation work is already underway and we expect to able to submit our IND in the beginning of 2009. We have now chosen to partner with SAFC Pharma for the production of our lead compound in support of clinical trials."
About Lytix Biopharma AS
The Scandinavian based company Lytix Biopharma commercialise world-class research in synthetic peptide therapeutics by its founding scientists working in the University Hospital and University of Troms in Norway. The initial pipeline includes micro-size synthetic antimicrobial peptides (SAMPs(TM)) for the treatment of multiresistant bacteria, fungal infections and cancer.
In addition to equity, the company and its research programme has received substantial grants from the Norwegian Research Council through its BIA and FUGE programmes. Lytix operates from state-of-the-art laboratories in the Troms Science Park with business development in Oslo. The development team has extensive experience of developing peptide based drugs, including preparation of peptides and peptidomimetics, synthesis of non-coded amino acids, medicinal chemistry, pharmacokinetics, QSAR and peptide drug design.
www.lytixbiopharma.com
Contacts
Corporate Inquiries
Lytix Biopharma AS
Oystein Rekdal - CEO
Tel +47 97 57 33 58
oystein.rekdal@lytixbiopharma.com
or
Media Inquiries
Hayhurst Media
Richard Hayhurst, +44 (0) 7711821527
Richard@hayhurstmedia.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.